Drug resistant hypertension is a clinically relevant problem, which has attracted increasing attention over the past few years. This is certainly due to a growing awareness of the importance of blood pressure (BP) control in reducing hypertension-related cardiovascular risk. It is also due, however, to a recent major technological breakthrough in the management of resistant hypertension, because of the introduction of two novel invasive therapeutic approaches: carotid baroreceptor stimulation and catheter based renal sympathetic denervation (RDN) 1, 2 . For a number of reasons the latter method seems to be taking the upper hand, and is used with growing enthusiasm all over the world, even if the strength of the evidence in its support is not currently overwhelming.
The concept of RDN derives from a known pressor effect of sympathetic stimuli, arriving to the kidney via efferent fibers located in the adventitia of renal arteries, in the frame of a complex regulation of sympathetic activity also including reflex modulation by renal afferent neural influences 3, 4, 5. Hence the hypothesis was made that destruction of these fibers, by bilaterally applying radiofrequency electrical current through an ablation catheter positioned inside renal artery, might reduce sympathetic activity in general. It was also hypothesized that, in particular, renal sympathetic fibers ablation might interfere with sympathetic renal modulation, leading to increased sodium and water excretion and to vasodilation, thereby effectively lowering elevated BP levels. This hypothesis has been first tested in animal studies 3, 4 and, subsequently explored in two major studies in humans: Symplicity HTN-1 6 and Symplicity HTN-2 7 followed by a growing number of reports from registries.
While the results of Symplicity studies clearly supported the efficacy of RDN in lowering office BP, their design left several major questions unanswered. One of the key issues was related to the fact that, strangely enough, resistant hypertension status was only defined based on
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Medical Agency to recommend that BP lowering efficacy by treatment should be assessed by means of ABPM in registration studies of antihypertensive drugs. 13 The above issues might be largely resolved when Symplicity HTN-3 trial results are available: this trial is in fact designed as a randomized study with a control group undergoing sham procedure, a blinded outcome assessment and with 24 h BP as a secondary outcome, and will exclude patients with controlled or mildly elevated 24 h BP 14 . At present, however, only non-randomized observations on the 24h ABP effects of RDN are available. Several such reports have been published until now, but the number of subjects included has been invariably small. 6, 15, 16 The paper by Mahfoud et al.
published in the current issue of Circulation, offers for the first time data on ambulatory BP changes after RDN in a relatively large sample (N= 346) of subjects who underwent RDN following the Symplicity protocol, and were followed over up to 12 months. 17 The principal result of the analysis carried out on such dataset is the demonstration that in true resistant hypertensives (i.e. patients with office SBP 160 mmHg, or 150 mmHg for diabetic patients, combined with 24 h SBP >130 mmHg in subjects treated with 3 antihypertensive drugs including a diuretic) clinically and statistically significant reductions occurred in ambulatory SBP and DBP (8-10 mmHg and 4-7 mmHg, respectively, at different follow-up times). Much larger reductions in office SBP and DBP also occurred (21-27 and 9-12 mmHg, respectively), which were however slightly less pronounced than in Symplicity studies. Ambulatory BP reductions were similar during daytime and night-time. Among possible predictors of response to RDN, only baseline BP resulted to be significantly related to BP reduction.
These results need to be placed in the context of previous studies comparing the effect of he number of subjects included has been invariably small. (systolic) and 47% (diastolic) of reduction in office systolic or diastolic BP, respectively, 17 these figures being higher than those reported in some of the previous studies. This data is shown in Figure 1 , which compares reductions in office and in 24h ambulatory BP reported in drug studies with the corresponding reductions described in the available RDN studies in which both methods of BP measurements were implemented ( Figure 1 ). 6, 7, 15, 16 , 17. This greater discrepancy between office and ambulatory BP reduction might be due to a Another interesting finding of the study by Mahfoud et al. 17 is that the reduction in nighttime BP was similar to that in daytime BP and, consequently, no improvement occurred in altered (nondipper or reverse dipper) circadian BP profiles 17 . While an additional benefit in this regard would be welcome, the finding that night-time BP is effectively reduced by RDN is nevertheless reassuring, on the background of the results of several studies and of a large metaanalysis which indicated that nocturnal BP may be more closely related to outcome compared with daytime BP levels 14 .
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The question remains open whether office BP lowering provides any benefit in these patients and, consequently, whether "pseudo-resistant" hypertensive patients should be considered eligible for this interventional approach.
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Apart from a nonrandomized and uncontrolled design, the study by Mahfoud et al. 17 has
another important limitation, that is a high rate of subjects lost to follow-up. In fact, follow-up ABPM data at 3 months are available only in 245 out of 346 patients who entered the study. The figure is similar at 6 months (236) and data at 12 months are available in only 90 subjects. This inevitably raises questions on possible biases due to the exclusion of a large subgroup of patients from the analyses. There may be also some doubts regarding the quality of ABPM recordings since as many as 47 patients failed to record night-time BP at baseline.
Despite these limitations, while waiting for the Symplicity-3 results, the study by
Mahfoud et al. 17 provides interesting novel insights into the efficacy of RDN, supporting use of this approach in patients with true resistant hypertension. At the same time, the results of this study emphasize the importance of combining out-of-office BP, and in particular 24h ABPM, to
properly assess the effects of RDN on hypertension control in daily life.
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